Skip to content

02186.HK

Luye Pharma Group Ltd.

HKSE · Healthcare · Drug Manufacturers - General · CN

HKD 1.90
+1.07%
Ask drillr

Year over year

Reported trailing growth

Revenue
-0.8%
EBITDA
+24.4%
EBIT
+32.3%
EPS
-15.5%
Free cash flow
+717.7%
Operating cash flow
-20.8%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+1.8%
EBITDA
+3.6%
EBIT
+12.2%
Net income
+0.8%
EPS
-2.0%
Free cash flow
+16.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026